Nievelstein Rutger A J, Borgwardt Lise, Inarejos Clemente Emilio J, Von Kalle Thekla, Kyncl Martin, Lequin Maarten H, Littooij Annemieke S, Pace Erika, Di Paolo Pier L, Van Rijn Rick R, Rogasch Julian M M, Schäfer Jurgen, Sefic Pasic Irmina, Spezzacatene Anita, Tolboom Nelleke, Wan Simon M, Zucchetta Pietro
Department of Radiology and Nuclear Medicine, Division Imaging and Oncology, University Medical Center Utrecht, Wilhelmina Children's Hospital, P.O. Box 85500, 3508, GA, Utrecht, Netherlands.
Department of Radiology and Nuclear Medicine, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Pediatr Radiol. 2025 Sep 2. doi: 10.1007/s00247-025-06372-6.
In paediatric oncology, imaging biomarkers play an increasing role in diagnostic imaging and research. They can be used for prediction, detection, staging, and grading of diseases, as well as for assessment of response to treatment. Imaging biomarkers are complementary to tissue-based biomarkers, enabling a more personalised approach in oncology care. In this white paper by the European Society of Paediatric Radiology (ESPR) Oncology Taskforce and European Association of Nuclear Medicine (EANM) Paediatrics Committee, an overview is given of the current knowledge on the use of imaging biomarkers in general and per tumour group.
在儿科肿瘤学中，影像生物标志物在诊断成像和研究中发挥着越来越重要的作用。它们可用于疾病的预测、检测、分期和分级，以及评估治疗反应。影像生物标志物是基于组织的生物标志物的补充，能够在肿瘤护理中采用更个性化的方法。在欧洲儿科放射学会（ESPR）肿瘤学特别工作组和欧洲核医学协会（EANM）儿科学委员会撰写的本白皮书中，概述了关于影像生物标志物的一般用途以及各肿瘤组的当前知识。
